Clarity in every critical moment

Labcorp meets every critical moment of oncology development with clarity, speed, and precision. Connect with Labcorp to explore how our scientific expertise can empower your oncology program at every stage.

ACMG Conference 2026

Together Labcorp and Invitae are empowering providers and patients with genetic testing insights that improve personalized care

The Pulse of the Oncologist

Cancer care is advancing at an unprecedented pace, yet oncologists are navigating mounting challenges as they work to deliver the best outcomes for their patients. Growing complexity, digital friction and persistent access gaps have made time the most critical currency in care. 

Paired tissue-liquid biopsy CGP approaches: Driving broader enrollment and better outcomes

Comprehensive genomic profiling (CGP) of tumor tissue is central to precision oncology, enabling detection of actionable mutations to inform treatment decisions. Significant strides have been made in increasing how many patients are eligible for tissue testing and in the number of targeted therapies available; however, tissue testing success rates vary by disease type and may miss known guideline-based mutations.1-3 By integrating liquid biopsy with tissue CGP workflows, sponsors can expand eligibility, uncover additional mutations and accelerate timelines—ultimately improving outcomes for patients and trials alike. 

Maximizing biomarker insights from minimal samples

Biomarker testing is central to oncology research and clinical care, driving targeted therapy development and personalized treatment. Next-generation sequencing (NGS) based approaches can detect diverse genomic alterations in a single assay, however, their broad adoption is hindered by the quality and quantity of available tumor samples.

Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 study

Colon cancer can recur after surgery. Doctors need better tools to identify who is most at risk. A new test can find small fragments of DNA from the tumour that circulate in blood, called ctDNA. If ctDNA is detected in the blood, it means that some cancer cells remained in the body after surgery. The study investigated whether finding ctDNA in the blood could predict the chance of colon cancer reappearing in patients with localized (stage III) disease who were treated with chemotherapy. 

Society for Maternal-Fetal Medicine (SMFM) Annual Pregnancy Meeting

We are empowering providers and patients with meaningful health data to pave the way for new treatments, targeted therapies and individualized healthcare.